The aim of this study is to assess treatment patterns, clinical outcomes, and patient characteristics among adults with metastatic castration-resistant prostate cancer (mCRPC) in the United States (US) real-world clinical practice. This study will be conducted using data extracted from the PRECISION (PRostatE Cancer dISease observatION) data platform.
Study Type
OBSERVATIONAL
Enrollment
17,111
Novartis
East Hanover, New Jersey, United States
RECRUITINGNumber of Patients by Prior Therapies
Time frame: Baseline
Number of Patients by Number of Post-index Lines of Therapy (LOTs)
Time frame: Up to approximately 5 years
Number of Patients by Type of Therapy at Each LOT
Time frame: Up to approximately 5 years
Percentage of Patients Switching From One Type of Therapy to Another at Each LOT
Time frame: Up to approximately 5 years
Time to First-line (1L) Treatment Initiation (TTTI)
Time from index date (mCRPC diagnosis) to the start of 1L treatment.
Time frame: Up to approximately 5 years
Time to Next Therapy (TTNT) for Each LOT
Time from the end of each LOT to initiation of the next LOT.
Time frame: Up to approximately 5 years
Number of Patients by Patient Characteristics
Patient characteristics include race, geographical region, insurance status, marital status, type of treatment center, comorbidities, Gleason score, disease stage at diagnosis, and prostate-specific antigen (PSA) level.
Time frame: Baseline
Age
Time frame: Baseline
Progression-free Survival (PFS) From Index Date
PFS from index date: time from mCRPC diagnosis (index date) until progression or death from any cause.
Novartis Pharmaceuticals
CONTACT
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: Up to approximately 5 years
PFS From Each LOT
PFS from each LOT, among those with that LOT: time from the date of initiation of the LOT until progression or death from any cause.
Time frame: Up to approximately 5 years
Overall Survival (OS) From Index Date
OS from index date: time from mCRPC diagnosis (index date) until death from any cause.
Time frame: Up to approximately 5 years
OS From Each LOT
OS from each LOT, among those with that LOT: time from the date of initiation of the LOT until death from any cause.
Time frame: Up to approximately 5 years